FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C. 20549
-------------	------------

Check this box if no longer subject						
o Section 16. Form 4 or Form 5						
bligations may continue. See						
netruction 1(h)						

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Ganot Ilan						2. Issuer Name and Ticker or Trading Symbol Solid Biosciences Inc. [SLDB]									all app Direc	or 10% Owne		Owner	
(Last) (First) (Middle) C/O SOLID BIOSCIENCES INC. 141 PORTLAND STREET, 5TH FLOOR						3. Date of Earliest Transaction (Month/Day/Year) 02/10/2022									below	,	e Other (specibelow) & President		
(Street) CAMBR (City)	4. If <i>i</i>	4. If Amendment, Date of Original Filed (Month/Day/Year)								Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person									
		Tab	le I - N	lon-Deriva	tive \$	Secui	rities	Ac	quire	d, Di	sposed of	, or B	enefici	ially	Own	ed			
Date			2. Transaction Date (Month/Day/	Execution Date				3. Transaction Code (Instr. 8)					Beneficially Owned Following		s ally following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership	
									Code	v	Amount	(A) or (D)	Price	Reporte Transac (Instr. 3		tion(s)			(Instr. 4)
Common Stock 02/10/				02/10/20	22				S		463(1)	D	\$1.120)2	2,5	518		I	Wife
Common Stock														1,202,093		D ⁽²⁾			
Common Stock															290,914		I		See Footnote ⁽³⁾
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	2. Conversio or Exercis Price of Derivative Security		Exec r) if an	Deemed sution Date, y tth/Day/Year)		ansaction of ode (Instr. Derivative				te Exer ration I th/Day		7. Title Amou Secur Under Deriva Secur 3 and	nt of ities lying itive ity (Instr.	Deri	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownersh Form: Direct (D or Indired (I) (Instr.	Beneficial Ownership (Instr. 4)
					Code	ode V (A) (D)			Date Exerc	cisable	Expiration Date	Title	of Shares						

Explanation of Responses:

- $1. \ This sale was made to cover withholding taxes following the vesting of the previously granted restricted stock units. The shares were sold pursuant to a written instruction under Rule <math>10b5-1(c)(1)$.
- 2. Represents 1,141,462 shares held by Mr. Ganot as an individual, and 60,631 shares held by Mr. Ganot and Annie Ganot as joint tenants with right of survivorship. Includes 2,272 shares acquired by Mr. Ganot under the Solid Biosciences Employee Stock Purchase Plan on September 1, 2021.
- 3. Represents 290,914 shares held by Adam Ganot and Annie Ganot, and their successors, as the trustees for the Ilan Ganot 2017 Irrevocable Trust dated March 3, 2017.

Remarks:

/s/ Erin P. Brennan as attorney-in-fact for Ilan Ganot

03/08/2022

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.